Pulmotect
HOUSTON, TX · Biotechnology · 9 employees
Pulmotect has developed PUL-042, an inhaled therapeutic which aims to boost the body's innate immune system resulting in highly-targeted lung protection against all major classes of pathogens including bacteria, fungi, and viral pathogens.
Funding history
- Venture - Series Unknown — $10.3M — Sep 2024
- Seed — $3.7M — Jan 2024
- Seed — $1.5M — Sep 2023
- Seed — $300K — Jun 2023
- Seed — $3.5M — Feb 2023
Recent signals
- Sep 09, 2024: Raised $10.3M in Venture - Series Unknown
- Jan 16, 2024: Raised $3.7M in Seed
- Sep 28, 2023: Raised $1.5M in Seed
- Jun 14, 2023: Raised $300K in Seed
- Feb 10, 2023: Raised $3.5M in Seed
- Jan 27, 2023: Raised $3.5M in Seed
- Feb 09, 2022: Raised $3.7M in Seed
- Mar 11, 2021: Raised $3.5M in Seed
See plans & pricing → Track Pulmotect’s funding, hiring, and signals — with verified contacts — on Fundz.